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Objectives: The aim of this study was to identify clinical parameters
associated with increased carotid intima media thickness (CIMT) in
adolescents with type 2 diabetes.
Background: Overweight children and adolescents are at increased risk
of type 2 diabetes and early development of atherosclerotic lesions and
cardiovascular complications.
Methods: Patients were selected among diabetics who presented to dia-
betes out patients’ clinic. Criteria for selection were age (12–19 years),
being overweight (BMI above the 95th percentile for age and gender),
normal or high C-peptide, and negative studies for islet cell antibodies.
Age and gender matched healthy subjects, were enrolled as a control
group. Laboratory investigations included lipid proﬁle, hypersensitive
C-reactive protein (hs-CRP), HbA1c and assessment of insulin resis-
tance by HOMA. According to HbA1c, patients were divided into,
uncontrolled group (with HbA1c >6.5) and controlled group (with
HbA1c 6 6.5). Ultrasonographic analysis of CIMT was performed
for all participants and its association with risk variables was analyzed.
Results: BMI, triglycerides, C-reactive protein, HbA1c and HOMA
were signiﬁcantly higher in diabetic patients than the controls. CIMT,
HbA1c, systolic blood pressure, triglycerides, HOMA and C-reactive
protein were signiﬁcantly higher in uncontrolled than controlled dia-
betics, while there was no signiﬁcant diﬀerence between the two groups
as regard BMI, total cholesterol, LDL, HDL and C-peptide. In dia-
betic patients, CIMT correlated positively with BMI, duration of dia-
betes, systolic and diastolic blood pressure, HbA1c, HOMA, and C
reactive protein.
Conclusion: CIMT is increased in adolescents with type 2 diabetes as
compared to control subjects. Poor glycemic control, HOMA,
increased C reactive protein, BMI, duration of diabetes and elevated
blood pressure are associated with early atherosclerosis in these
patients.
http://dx.doi.org/10.1016/j.ehj.2013.12.014
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Introduction: The fenetylline (captagon) tablets (an amphetamine like
substance) are a stimulant drugs which are widely used in the Arabian
Peninsula.
Objectives: The aim of this study was to evaluate the clinical character-
istics and outcome of acute heart failure in patients using captagon
tablets.
Methods: From September, 2009, through December, 2011, 280 con-
secutive patients with acute dilated cardiomyopathy and acute heart
failure syndrome presented to emergency department in one tertiary
care center in Saudi Arabia were enrolled in this study. Patients were
divided into 2 groups group I (40 patients) were captagon users and
group II (240) were captagon non-users. Captagon use was elicited
mainly by history taking on admission. Patients with coronary artery
disease were excluded.
Results: Fourteen percent of patients (40 patients) were captagon
users. Captagon users were younger (mean age in years of 23 ± 12
vs. 28 ± 9) and almost all of them were male (98% vs. 72%). About
40 % of captagon users were alcohol users and about 92% of them
were smokers. Overall, captagon users had higher risk of in-hospital
death (7% vs. 4%, p value <0.05), cardiogenic shock (15% vs. 8%,
p value <0.05), pulmonary tuberculosis (7% vs. 1%, p value <0.05)
and recurrent admission with heart failure (35% vs. 24%, p value
<0.05). After adjustment for baseline variability, captagon use was
found to be an independent risk factor of death and for recurrent
admission in patients presented with cardiomyopathy and acute heart
failure.
Conclusios: Captagon use was found to be an independent risk factor
of death and other morbidities in patients presented with cardiomyop-
athy and acute heart failure. Our study underscores the importance of
improving education concerning the cardiac risks of captagon use.
http://dx.doi.org/10.1016/j.ehj.2013.12.015
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Background: The clinical outcome in diabetic patients undergoing
percutaneous coronary intervention (PCI) is inferior to that in
non-diabetic patients. Several aspects of diabetic coronary artery
disease appear to be responsible for this observation. In comparison
with stainless steel stent, cobalt chromium stent has a higher radial
strength and radio-opacity for similar electronegativity, this allow
for the production of thinner struts with a similar radiological
visibility.
Therefore we studied and compared six-months prognosis of cobalt
chromium stent versus stainless steel Bare metal stents in diabetic
patients undergoing PCI.
Methods and Results: Our study included seventy diabetic patients
with Ischemic heart disease amendable to percutaneous stenting with
stents P3 mm in diameter and 625 mm length. They were randomly
assigned to cobalt chromium stents (Group I) or stainless steel stents
(Group II). PCI was done with initial success and we excluded patients
with unsuccessful PCI or complications during intervention, using
stainless steel stent and chromium stent in the same lesion, left main
stem lesions, osteal and bifurcational lesions.
Our primary end point was Major adverse cardiac events (death,
Myocardial infarction, unstable angina, emergency CABG or target
lesion revascularization); over period of 6 months and our secondary
end point was in-stent restenosis assessed by coronary angiography
at 6 months in the follow up period.
Total MACE in group (I) was 9 patients, coronary angiogra-
phy was done for those patients after the cardiac event, that
showed 7 patients with ISR and 2 of them showed patent stents.
Patients without MACE whom undergone follow up coronary
angiography after 6 months, revealed 6 patients suﬀered ISR
out of 23 patients.
While total MACE in group (II) was 5 patients, coronary angiog-
raphy for those patients showed 4 patients with ISR and 1 of them
showed patent stent. Patients without MACE whom undergone follow
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